Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FCN-159 in Brain Arteriovenous Malformations
NCT06913725Phase 2Recruiting
- Sponsor
- Xuanwu Hospital
- Start
- Feb 2025
- Primary completion
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of luvometinib in brain arteriovenous malformation (AVM) (2 arms), sponsored by Xuanwu Hospital. Primary endpoint: Objective Response Rate assessed by Silence-MRA at 1 year. Started Feb 2025; status: recruiting.
02
Drugs
luvometinib
03
Conditions
brain arteriovenous malformation (AVM)
Beyond the preview
Go deeper on NCT06913725.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06913725.